Why Ovarian Cancer Stops Responding to Chemo — And How Scientists Are Fighting Back

Almost every woman treated for advanced ovarian cancer knows some version of this story. The first round of chemotherapy works. Scans improve. Numbers come down. There’s a stretch of time that feels almost like ordinary life.

And then it comes back, and the same drugs don’t work as well. Or at all.

For decades, the explanation was essentially genetic: cancer cells mutate, some mutations happen to make cells drug-proof, and those cells survive to repopulate the tumor. That isn’t wrong. It just turned out to be a fraction of the story.

July brought four studies — from the Wistar Institute, MD Anderson, and Memorial Sloan Kettering — that together reframe drug resistance as something much stranger. The cancer isn’t only mutating. It’s recruiting help, changing the neighborhood, and using its own waste products as weapons.

Study one: chemotherapy calls in the wrong reinforcements

The finding that struck us hardest came from Dr. Nan Zhang’s team at the Wistar Institute, published in the Journal for ImmunoTherapy of Cancer.

They found that chemotherapy triggers an inflammatory cascade that ends up protecting the tumor. Here’s the chain of events, in plain terms.

Chemotherapy kills cells, and dying cells make a mess. Your body reads that mess as damage and responds the way it responds to any injury: with inflammation. Levels of a signaling protein called IL-1β (interleukin-1 beta) climb — and they climb highest in exactly the women whose cancers go on to resist treatment.

IL-1β is a summons. It lands on the structural cells within the tumor, which respond by releasing chemical signals that call in neutrophils — the immune system’s first responders, the cells that flood into any cut or infection.

Neutrophils are supposed to be helpful. Here, they do three unhelpful things at once.

They exhaust your T cells — the immune cells that actually kill cancer. Overwhelmed by inflammatory signals, T cells slide into a burned-out state where they’re still present but no longer effective, like a security guard on the fortieth hour of a shift.

They cast nets. Neutrophils have a dramatic last resort called NETosis: they rupture themselves and fling out a web of DNA and proteins — a neutrophil extracellular trap, or NET — designed to snare bacteria. Against a tumor, those sticky webs become a physical shield, tangling up the chemotherapy drugs and immune cells trying to reach the cancer.

And they blunt the drugs directly, reducing chemotherapy’s effect on the cells that are left.

So the treatment triggers inflammation, inflammation summons firefighters, and the firefighters build a wall around the fire.

As Zhang put it: “Our findings suggest it is also an immunology problem. The treatment meant to kill the tumor can trigger inflammatory responses that help it survive.”

Here’s the hopeful part. When the researchers blocked NET formation in the lab, chemotherapy started working again. And the summons at the top of the chain — IL-1β — is already the target of drugs approved for other conditions, mostly inflammatory and autoimmune diseases. The team proposes combining an IL-1β blocker with immune checkpoint inhibitors to keep T cells in the fight and restore chemotherapy sensitivity — a strategy built from drugs that already exist, which is the fastest kind there is.

Study two: a signal that loosens the glue

A second Wistar study, published in Nature Aging, looked at what chemotherapy-surviving cells get up to afterward — and found something no one was looking for.

Some cancer cells survive chemotherapy without going back to dividing. They just sit there. As lead researcher Aidan Cole described it: “Some cancer cells that survive chemotherapy aren’t dividing anymore, but they’re still biologically active.”

What they’re doing is talking. These survivors release fructose — the same simple sugar found in fruit and in a great deal of processed food — and it carries an unexpected message to the cells around them: make less cholesterol. And cholesterol, as we wrote about in April’s piece on the SQLE discovery, is a structural component of cell membranes. It’s part of what makes cells sticky enough to hold onto each other.

Less cholesterol, less glue. Cells that were stuck in place come loose — and loose cancer cells travel. In ovarian cancer that matters more than almost anywhere else, because this disease spreads by shedding cells into the abdominal cavity, where they drift and take root on other organs.

Senior author Katherine Aird noted that the implications may run wider: “Other cancers that spread within the torso — pancreatic, colon, liver — could behave similarly.”

Now the caveats, and please read them. This was preclinical work — cells and animal models, not people. There’s also an uncomfortable wrinkle: statins, taken by roughly 39 million Americans, lower cholesterol and had similar effects on cell adhesion in these experiments.

Do not stop taking a statin because of this study. The researchers said so plainly. Statins prevent heart attacks and strokes, and that benefit is proven in millions of people over decades. This is a laboratory observation about a mechanism, not advice about your medicine cabinet. The same goes for diet: no one has tested whether changing what a woman with ovarian cancer eats changes what her cancer does. We’d rather tell you that than let you build a hope on it.

Study three: the tumor’s own acidity, turned against it

Researchers at MD Anderson, led by Rugang Zhang, PhD, and Kaixin Cheng, PhD, went after a different resistance problem — this one involving PARP inhibitors, and it needs a little background.

A gloved hand using a pipette to transfer DNA into a micro test tube — PARP inhibitors work by cutting off a cancer cell's last remaining way to repair its own DNA.

Your cells break their own DNA constantly and repair it constantly, using two main repair crews. BRCA genes run one. PARP runs the other. Cancers with a broken BRCA gene have already lost the first crew and survive on the second — so PARP inhibitors take out that second crew too, leaving the cancer with no way to fix its own DNA until the damage piles up and the cell collapses. Healthy cells still have their BRCA crew and shrug the drug off. It’s one of the most elegant ideas in modern oncology, and it has genuinely changed ovarian cancer treatment.

PARP inhibitors also stop working over time, and the MD Anderson team found part of the reason in something nobody suspected: the tumor’s acidity. Tumors grow faster than their blood supply can keep up with, burn fuel inefficiently, and dump acidic waste around themselves. That has always been filed away as a side effect of tumor life — messy, but incidental.

Using a CRISPR screen — a technique that switches off genes one at a time to see which ones the cancer can’t live without under specific conditions — the team found that acidity switches on a survival pathway, and that its top hit was a protein called p300.

p300 is an epigenetic activator: think of it as a volume knob on your genes. It doesn’t change the genetic code, it changes how loudly particular genes get read. In an acidic tumor, p300 turns up exactly the genes that let the cancer shrug off a PARP inhibitor. When the researchers blocked p300, sensitivity to olaparib — a widely used PARP inhibitor — came back.

The practical implications are unusually close to hand. Several p300 inhibitors already exist in preclinical and early clinical development, including one called IACS-16559 developed at MD Anderson. And because acidity is a feature of most solid tumors, the same approach may reach well beyond this disease.

Study four: a door on almost every ovarian tumor

The last piece of July news is quieter and, we think, quietly important.

At Memorial Sloan Kettering, a team led by postdoctoral researcher Qinyu Zhu, PhD, working with Melinda Diver, PhD, in MSK’s Structural Biology Program, published the first detailed three-dimensional images of a protein called SLC34A2 in the Proceedings of the National Academy of Sciences.

SLC34A2 is a phosphate transporter — a doorway in the cell membrane that lets phosphate in. It is overexpressed in 80–90% of ovarian tumors, and that number is why this matters. Most targeted therapies help a slice of patients: mirvetuximab reaches the roughly quarter of women with high folate receptor alpha; pembrolizumab is for PD-L1-positive tumors. A target present on the large majority of ovarian cancers is a rare and valuable thing.

The team used cryo-electron microscopy — flash-freezing the protein and photographing it with an electron beam, which reveals shapes far too small for any light microscope — to capture SLC34A2 in several positions as it works. Knowing the exact shape of a target, in motion, is what lets chemists design a drug that fits it. The MSK team describes their structures as “a roadmap for developing better drugs” — and experimental therapies aimed at SLC34A2 are already in clinical trials.

What all four have in common

Read together, these studies say something bigger than any one of them. Drug resistance isn’t only about cancer cells changing. It’s about cancer changing its surroundings — recruiting your immune cells to build walls, signaling neighbors to let go and travel, exploiting the acidity of its own neighborhood to switch on protective genes.

That’s daunting. It also means far more places to intervene than we thought. You don’t have to out-mutate a tumor if you can cut the summons that brings the firefighters, or dissolve the nets, or turn down the volume knob the acidity turned up. And nearly every one of these strategies would use a drug that already exists or is already in trials — which is what tends to happen once you finally understand a mechanism. The tools are often already on the shelf.

If you’re in this right now

None of this is available at your clinic this month, and we won’t pretend otherwise. But some of it is worth knowing about anyway:

If a PARP inhibitor is losing ground, ask your oncologist whether any combination trials — p300 inhibitors or otherwise — are open to you.
If your cancer has become platinum-resistant, ask whether trials combining chemotherapy with anti-inflammatory or immune-modulating drugs are enrolling.
Ask what your tumor has been tested for, and keep a copy of your pathology report. As targets like SLC34A2 reach the clinic, what your particular cancer expresses is what determines which doors are open to you.
And please don’t change your medications or overhaul your diet based on a preclinical study, the fructose one included. Bring it to your care team and let them tell you what it means for you.

The next few years of treatment will probably be less about finding one perfect drug and more about combinations — a chemotherapy, plus something that stops the tumor from defending itself against it. Researchers just spent this month mapping those defenses in more detail than we’ve ever had. You can’t dismantle what you can’t see. Now we can see it.

Sources